Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 11Sarcoma 2Thoracic 1Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Multiple Endocrine Neoplasia Type 1 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymus Neoplasms 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Diseases 1Paraganglioma 1Pancreatic Neoplasms 1Obesity 1Midgut Neuroendocrine Tumors 1High Grade Neuroendocrine Neoplasms 1Brain Neoplasms 1Atherosclerosis 1Adrenocortical Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 3entrectinib 2Radiotherapy 2Proton Therapy 2Fluorodeoxyglucose F18 2FAPI-46 2tipifarnib 1pegvisomant 1fluorodopa F 18 1entinostat 1dactolisib 1alectinib 1Trastuzumab 1Tamoxifen 1Surveys and Questionnaires 1Specimen Handling 1Ritonavir 1Respiratory Therapy 1Radiation Dose Hypofractionation 1Quality of Life 1Protons 1Positron-Emission Tomography 1Photochemotherapy 1Patient Reported Outcome Measures 1Octreotide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Indinavir 1Immunotherapy 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Blood Specimen Collection × Endocrine × Clear all
NCT03465618 2026-05-01

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
CNSEndocrine

Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡